Yahoo Finance EN

Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16

Mar 20, 2026 &03112020202631; 20:11 UTC finance.yahoo.com

Read original on finance.yahoo.com ↗

→

Neutral impact

Sentiment score: +20/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Jefferies has raised its price target for CytomX Therapeutics (CTMX) to $16, signaling potential optimism about the biotech firm's prospects amid ongoing drug development efforts. However, this analyst action may not translate to immediate stock gains if the market has already anticipated such upgrades or if broader sector challenges persist. Overall, the impact could be limited without additional catalysts like clinical trial results.

AI CONFIDENCE

40% Moderate

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

CTMX

CTMXStock

Expected to rise

Jefferies' price target raise suggests positive analyst views on CytomX Therapeutics' pipeline, but this could be already priced in or overshadowed by biotech sector volatility.

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Monitor CTMX for short-term price movements following the upgrade, but consider waiting for confirmatory news like earnings or trial data before entering a position, as analyst actions alone may not drive sustained gains.

KEY SIGNALS

Analyst price target increase

SECTORS INVOLVED

Biotechnology

Analysis generated on Mar 22, 2026 at 21:40 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16

RELATED INTELLIGENCE